Trial Profile
Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 27 Jun 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 31 May 2011 New trial record